El interés en corto de Zevia da a los inversores una idea del grado en que los inversores apuestan por la caída de las acciones de Zevia. Los datos de interés en corto se actualizan cada dos semanas.

Zevia (NYSE:ZVIA) Bolsa, Informe de interés en corto

ZEVIA PBC-A

Zevia

Zevia PBC is a beverage company disrupting the liquid refreshment beverage industry through refreshing, zero-calorie, zero-sugar, naturally sweetened beverages that are all Non-GMO Project Verified. It offers a platform of products that include a variety of flavors across Soda, Energy Drinks, Organic Tea, Mixers, Kidz drinks, and Sparkling Water. Its products are distributed across the U.S. and Canada through a network of retailers in the food, drug, mass, natural, and e-commerce channels. The company derives a majority of its revenue from the United States.

Zevia PBC

Waste Connections (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WCN#NYSE">WCN</a>) has outperformed the market over the past 10 years by 9.58% on an annualized basis producing an average annual return of 19.98%. Currently, Waste Connections has a market capitalization of $50.53 billion. 
Buying $1000 In WCN: If an investor had bought $1000 of WCN stock 10 years ago, it would be worth $6,175.58 today based on a price of $195.56 for WCN at the time of writing.
<h3>Waste Connections's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1746745218_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

News

Trading Ideas

If You Invested $1000 In This Stock 10 Years Ago, You Would Have This Much Today

Genmab (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GMAB#NASDAQ">GMAB</a>) reported quarterly earnings of $0.31 per share which beat the analyst consensus estimate of $0.23 by 34.78 percent. This is a 6.9 percent increase over earnings of $0.29 per share from the same period last year. The company reported quarterly sales of $715.00 million which missed the analyst consensus estimate of $748.58 million by 4.49 percent. This is a 19.08 percent increase over sales of $600.43 million the same period last year.

Earnings

Earnings Beats

Earnings Misses

GMAB

Genmab Q1 EPS $0.31 Beats $0.23 Estimate, Sales $715.00M Miss $748.58M Estimate

CeriBell (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CBLL#NASDAQ">CBLL</a>) raises FY2025 sales outlook from $81.00 million-$85.00 million to $83.00 million-$87.00 million vs $83.72 million estimate.

Guidance

CBLL

CeriBell Raises FY2025 Sales Guidance from $81.00M-$85.00M to $83.00M-$87.00M vs $83.72M Est

HCI Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HCI#NYSE">HCI</a>) reported quarterly earnings of $5.35 per share which beat the analyst consensus estimate of $4.38 by 22.15 percent. This is a 46.58 percent increase over earnings of $3.65 per share from the same period last year. The company reported quarterly sales of $216.43 million which beat the analyst consensus estimate of $214.89 million by 0.72 percent. This is a 4.75 percent increase over sales of $206.61 million the same period last year.

HCI Group Q1 EPS $5.35 Beats $4.38 Estimate, Sales $216.43M Beat $214.89M Estimate

Inseego (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INSG#NASDAQ">INSG</a>) reported quarterly losses of $(0.16) per share which missed the analyst consensus estimate of $(0.08) by 100 percent. This is a 63.64 percent increase over losses of $(0.44) per share from the same period last year. The company reported quarterly sales of $31.67 million which missed the analyst consensus estimate of $32.06 million by 1.20 percent. This is a 29.63 percent decrease over sales of $45.01 million the same period last year.

INSG

Inseego Q1 EPS $(0.16) Misses $(0.08) Estimate, Sales $31.67M Miss $32.06M Estimate

ZipRecruiter (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZIP#NYSE">ZIP</a>) sees Q2 sales of $108.000 million-$114.000 million vs $114.22 million analyst estimate.

ZipRecruiter Sees Q2 Sales $108.000M-$114.000M vs $114.22M Est

AVITA Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RCEL#NASDAQ">RCEL</a>) affirms FY2025 sales outlook from $100.00 million-$106.00 million to $100.00 million-$106.00 million vs $102.26 million estimate.

RCEL

AVITA Medical Affirms FY2025 Commercial Revenue Guidance of $100.00M-$106.00M vs $102.26M Est

Mach Natural Resources (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MNR#NYSE">MNR</a>) reported quarterly earnings of $0.31 per share which missed the analyst consensus estimate of $0.63 by 50.79 percent. This is a 29.55 percent decrease over earnings of $0.44 per share from the same period last year. The company reported quarterly sales of $226.77 million which missed the analyst consensus estimate of $254.54 million by 10.91 percent. This is a 5.18 percent decrease over sales of $239.16 million the same period last year.

CORRECTION: Mach Natural Resources Q1 Adj. EPS $0.31 Misses $0.63 Estimate, Sales $226.77M Miss $254.54M Estimate

Varex Imaging (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VREX#NASDAQ">VREX</a>) is looking for Q3 Adj EPS of $(0.05)-$0.10 vs $0.16 analyst estimate. sees sales of $180.000 million-$200.000 million vs $210.00 million analyst estimate.

VREX

Varex Imaging Sees Q3 Adj EPS $(0.05)-$0.10 vs $0.16 Est; Sees Sales $180.000M-$200.000M vs $210.00M Est

Shareholders of UnitedHealth Group, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>) filed a class-action lawsuit on Wednesday accusing the company of misleading investors by concealing the negative business impacts that followed the December 2024 killing of UnitedHealthcare <a href="https://www.benzinga.com/news/legal/25/02/43887520/luigi-mangione-back-in-court-friday-supporters-donate-500k-to-suspected-killer">CEO Brian Thompson.</a>
The Details: The lawsuit alleges UnitedHealth withheld critical information regarding the backlash and regulatory scrutiny that arose after the CEO's death, particularly concerning the company's aggressive claims denial practices.&nbsp;
Read Next: <a href="https://www.benzinga.com/general/travel/25/05/45260938/disneys-new-abu-dhabi-theme-park-will-be-authentically-disney-and-distinctly-emirati-ceo-bob-iger-says?utm_source=articleShare">Disney&#8217;s New Abu Dhabi Theme Park Will Be &#8216;Authentically Disney And Distinctly Emirati,&#8217; CEO Bob Iger Says&nbsp;</a>
According to the plaintiffs, the public outcry and scrutiny forced strategic, more "patient-friendly" changes that would reduce the company's profitability.
UnitedHealth had initially forecasted adjusted earnings per share between $29.50 and $30 for 2025 and reaffirmed this outlook in January 2025, despite mounting public and regulatory pressures.&nbsp;
However, on April 17, 2025, the company revised its 2025 profit forecast downward to a range of $26 to $26.50. UnitedHealth stock plunged 22.4%, wiping out approximately $119 billion in market value in one day.&nbsp;
The shareholders contend UnitedHealth's failure to disclose the shift away from its previously aggressive claim denial strategies and the resulting impact on profitability constituted materially false and misleading statements. 
The lawsuit was filed in federal court in Manhattan and named UnitedHealth executives, including CEO Andrew Witty and CFO John Rex, as defendants. It covers the period from Dec. 3, 2024, to April 16, 2025, and seeks damages for shareholders who purchased UnitedHealth shares during that time.
&#8220;The company denies any allegations of wrongdoing and intends to defend the matter vigorously,&#8221; a UnitedHealthcare spokesperson said in a statement to NBC News.&nbsp;
Read Next:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/news/legal/25/05/45226604/president-trump-wants-to-reopen-alcatraz-heres-what-it-would-take?utm_source=articleShare">President Trump Wants To Reopen Alcatraz: Here&#8217;s What It Would Take</a></li>
</ul>
Image: Shutterstock

Health Care

Legal

Management

Insurance

General

UnitedHealth Investors Claim Company Hid Profit Impact Of CEO's Murder

Oracle (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ORCL#NYSE">ORCL</a>) has outperformed the market over the past 20 years by 5.21% on an annualized basis producing an average annual return of 13.37%. Currently, Oracle has a market capitalization of $422.43 billion. 
Buying $1000 In ORCL: If an investor had bought $1000 of ORCL stock 20 years ago, it would be worth $12,170.04 today based on a price of $150.64 for ORCL at the time of writing.
<h3>Oracle's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1746744319_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ORCL

Here's How Much $1000 Invested In Oracle 20 Years Ago Would Be Worth Today

Strattec Security (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STRT#NASDAQ">STRT</a>) reported quarterly earnings of $1.50 per share which beat the analyst consensus estimate of $0.95 by 57.89 percent. This is a 305.41 percent increase over earnings of $0.37 per share from the same period last year. The company reported quarterly sales of $144.08 million which beat the analyst consensus estimate of $140.84 million by 2.30 percent. This is a 2.35 percent increase over sales of $140.77 million the same period last year.

STRT

UPDATE: Strattec Security Q3 Adj. EPS $1.50 Beats $0.95 Estimate, Sales $144.08M Beat $140.84M Estimate

LPL Finl Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LPLA#NASDAQ">LPLA</a>) reported quarterly earnings of $5.15 per share which beat the analyst consensus estimate of $4.67 by 10.28 percent. This is a 22.33 percent increase over earnings of $4.21 per share from the same period last year. The company reported quarterly sales of $3.67 billion which beat the analyst consensus estimate of $3.27 billion by 12.11 percent. This is a 29.54 percent increase over sales of $2.83 billion the same period last year.

LPLA

CORRECTION: LPL Finl Hldgs Q1 Adj. EPS $5.15 Beats $4.67 Estimate, Sales $3.67B Beat $3.27B Estimate

Affirm Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AFRM#NASDAQ">AFRM</a>) reported quarterly earnings of $0.01 per share which beat the analyst consensus estimate of $(0.03) by 133.33 percent. This is a 102.33 percent increase over losses of $(0.43) per share from the same period last year. The company reported quarterly sales of $783.13 million which beat the analyst consensus estimate of $783.03 million by 0.01 percent. This is a 35.92 percent increase over sales of $576.16 million the same period last year.

AFRM

CORRECTION: Affirm Holdings Q3 EPS $0.01 Beats $(0.03) Estimate, Sales $783.13M Beat $783.03M Estimate

Additionally, the board has authorized a new share repurchase program of up to $1 billion of the company's common shares. This replaces the recently completed $1 billion share repurchase program, which was authorized in September 2021. In the second quarter of 2025, the company executed the remainder of its prior authorization by repurchasing approximately $74 million of common shares. Repurchases under the new program may be made through a variety of methods, including but not limited to open market purchases, unsolicited or solicited privately negotiated transactions, tender offers, block trades, accelerated share repurchase transactions, or pursuant to 10b5-1 trading plans.

Buybacks

Weyerhaeuser Authorizes New $1B Share Repurchase Program

Alcoa Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AA#NYSE">AA</a>, ASX: AAI))) (the "Company" or "Alcoa") announced that its Board of Directors (the "Board") has named Thomas J. Gorman as non-executive Chairmanof the Board, effective today, May 8, 2025, immediately upon the conclusion of the Company's 2025 Annual Meeting of Stockholders. Mr. Gorman has served as an independent director of the Board since May 2021, and succeeds Steven W. Williams in that position, who stepped down from the Board effective today after over eight years of service.

Alcoa Corporation Names Thomas J. Gorman As Board Chairman, Effective today, May 8, 2025

Four Corners Property Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FCPT#NYSE">FCPT</a>), a real estate investment trust primarily engaged in the ownership and acquisition of high-quality, net-leased restaurant and retail properties ("FCPT" or the "Company"), is pleased to announce the acquisition of three Express Oil Change &amp; Tire Engineers properties for $9.5 million. The properties are located in highly trafficked corridors in Georgia and are corporate-operated under long term, triple net leases with approximately 19 years of term remaining. The transaction was priced at a 6.6% cap rate on rent as of the closing date and exclusive of transaction costs.

FCPT

FCPT Announces Acquisition Of 3 Express Oil Change & Tire Engineers Properties For $9.5M

Alnylam Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALNY#NASDAQ">ALNY</a>) has outperformed the market over the past 15 years by 8.93% on an annualized basis producing an average annual return of 20.2%. Currently, Alnylam Pharmaceuticals has a market capitalization of $33.44 billion. 
Buying $100 In ALNY: If an investor had bought $100 of ALNY stock 15 years ago, it would be worth $1,535.06 today based on a price of $258.35 for ALNY at the time of writing.
<h3>Alnylam Pharmaceuticals's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1746743413_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ALNY

$100 Invested In Alnylam Pharmaceuticals 15 Years Ago Would Be Worth This Much Today

Clearfield (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLFD#NASDAQ">CLFD</a>) is looking for Q3 GAAP EPS of $0.01-$0.08 vs $(0.06) analyst estimate. sees sales of $45.000 million-$50.000 million vs $47.88 million analyst estimate.

CLFD

Clearfield Sees Q3 GAAP EPS $0.01-$0.08 vs $(0.06) Est; Sees Sales $45.000M-$50.000M vs $47.88M Est

Clearfield (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLFD#NASDAQ">CLFD</a>) affirms FY2025 sales outlook from $170.00 million-$185.00 million to $170.00 million-$185.00 million vs $177.55 million estimate.

Clearfield Affirms FY2025 Sales Guidance of $170.00M-$185.00M vs $177.55M Est

Press Releases

Zevia Releases Holiday Ad Shining Light on Artificiality - both in Commercials and in Soda

Zevia to Participate in the 27th Annual ICR Conference

Zevia Expects Fourth Quarter 2024 Net Sales of Approximately $39.5 Million

Zevia to Announce Fourth Quarter and Full Year 2024 Results on Wednesday, February 26, 2025

Zevia Announces Fourth Quarter and Full Year 2024 Results

Zevia 'Gets the Fake Outta Here' in New Campaign Starring Country Music Superstar Jelly Roll

Zevia to Announce First Quarter 2025 Earnings Results on May 7, 2025

Zevia Announces May Conference Participation

Small Cap

Opinion

Beverage Brands Are Moving From Flavor to Function and It's Paying Off for Investors

Zevia Announces First Quarter 2025 Results

CELH

COCO

SHOT

ZVIA

Embotelladora Andina S.A. Common Stock

Celsius Holdings

The Vita Coco Company, Inc. - Common Stock

Vita Coco

Coca-Cola Consolidated, Inc. - Common Stock

Coca-Cola Consolidated

National Beverage

Fomento Economico Mexicano S.A.B. de C.V. Common Stock

Fomento Economico

Keurig Dr Pepper

Coca-Cola

Coca Cola Femsa S.A.B. de C.V. American Depositary Shares, each representing 10 Units (each Unit consists of 3 Series B Shares and 5 Series L Shares)

Coca-Cola Femsa SAB de

Monster Beverage Corporation - Common Stock

Monster Beverage

PepsiCo

Primo Brands Corporation Class A Common Stock

Comments

Zevia

Interés en corto

Zevia (NYSE:ZVIA) Bolsa, Informe de interés en corto

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL